Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

NEUROCRINE Aktie

 >NEUROCRINE Aktienkurs 
113.7 EUR    -0.6%    (TradegateBSX)
Ask: 114.45 EUR / 90 Stück
Bid: 113.7 EUR / 90 Stück
Tagesumsatz: 118 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
NEUROCRINE Aktie über LYNX handeln
>NEUROCRINE Performance
1 Woche: -0,2%
1 Monat: -0,4%
3 Monate: -4,6%
6 Monate: -1,9%
1 Jahr: +21,5%
laufendes Jahr: -6,8%
>NEUROCRINE Aktie
Name:  NEUROCRINE BIOSCI. DL-001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US64125C1099 / 900964
Symbol/ Ticker:  NB3 (Frankfurt) / NBIX (NASDAQ)
Kürzel:  FRA:NB3, ETR:NB3, NB3:GR, NASDAQ:NBIX
Index:  -
Webseite:  http://www.neurocrine.com..
Profil:  Neurocrine Biosciences Inc. is a neuroscience-focused biopharmaceutical company specializing in the discovery, development, and commercialization of treatments for neurological, neuropsychiatric, endocrine, and metabolic disorders. Its flagship produ..
>Volltext..
Marktkapitalisierung:  11525.61 Mio. EUR
Unternehmenswert:  10666.83 Mio. EUR
Umsatz:  2478.09 Mio. EUR
EBITDA:  577.49 Mio. EUR
Nettogewinn:  414.62 Mio. EUR
Gewinn je Aktie:  4.17 EUR
Schulden:  408.29 Mio. EUR
Liquide Mittel:  617.68 Mio. EUR
Operativer Cashflow:  678.06 Mio. EUR
Bargeldquote:  1.99
Umsatzwachstum:  7.05%
Gewinnwachstum:  23.6%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  NEUROCRINE
Letzte Datenerhebung:  05.04.26
>NEUROCRINE Kennzahlen
Aktien/ Unternehmen:
Aktien: 100.36 Mio. St.
Frei handelbar: 97.27%
Rückkaufquote: 0.29%
Mitarbeiter: 2000
Umsatz/Mitarb.: 1.24 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 34.57%
Bewertung:
KGV: 28.7
KGV lG: 22.25
KUV: 4.65
KBV: 4.12
PEG-Ratio: 0.66
EV/EBITDA: 18.47
Rentabilität:
Bruttomarge: 98.18%
Gewinnmarge: 16.73%
Operative Marge: 22.25%
Managementeffizenz:
Gesamtkaprendite: 11.13%
Eigenkaprendite: 16.38%
>NEUROCRINE Peer Group
Gesundheit, Neurologische- & psychische Behandlung/ Medizin, Diabetes- & Adipositas- Behandlung
 
26.03.26 - 13:33
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings (PR Newswire)
 
Expert panel establishes structured approach to tardive dyskinesia screening, diagnosis and treatment in long-term care, including use of VMAT2 inhibitors New post-hoc KINECT‑PRO™ analysis in adults aged 65 years and older demonstrates clinically meaningful patient-reported improvements......
23.03.26 - 16:06
Biocom Appoints New Members to Its Board of Directors (Business Wire)
 
SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO--(BUSINESS WIRE)--#boardofdirectors--Biocom, the largest life science membership association, representing companies across California and major life science markets, today announced the appointment of Aaron K. Cohen, vice president, government affairs and public policy at Neurocrine Biosciences and Bradley Wolff, senior managing director at Evercore, to its board of directors. “Mr. Cohen and Mr. Wolff are valuable additions to our board of directors, which consists of prominent life science leaders with deep industry knowledge representing regions across the state,” said Tim Scott, president and CEO of Biocom. “As the life science industry evolves, we rely on the expertise and insight from our board to ensure we continue to equip member companies with vital resources as well as advance key initiatives that foster growth and innovation.” Aaron K. Cohen leads federal and state government affairs and public policy teams as the head of Neurocrine ...
17.03.26 - 23:42
Neurocrine auf dem Stifel CNS Forum: Unternehmen bekräftigt Wachstumsstrategie und zuversichtlichen Ausblick (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
17.03.26 - 21:09
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer (PR Newswire)
 
SAN DIEGO, March 17, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer. In his new role, Dr. Ratz will lead the company's global technical......
10.03.26 - 21:03
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum (PR Newswire)
 
SAN DIEGO, March 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the Stifel 2026 Virtual CNS Forum at 4:30 PM EST on March 17, 2026. The live webcast can be accessed on Neurocrine Biosciences'......
09.03.26 - 15:42
Neurocrine auf der Leerink-Konferenz: Wachstumsstrategie und Pipeline im Fokus (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
06.03.26 - 23:03
BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX) (PR Newswire)
 
TROY, Mich., March 6, 2026 /PRNewswire/ -- Equifax Inc.'s recent report has investors wondering if the company's stock is fairly valued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Equifax (NYSE: EFX) as......
04.03.26 - 06:48
Neurocrine auf der TD Cowen Health Conference: Strategische Einblicke in Wachstum und Pipeline (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
24.02.26 - 22:03
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March (PR Newswire)
 
SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences: TD Cowen 46th Annual Health Care Conference. Fireside chat on Tuesday, March 3, 2026 at 11:50 AM......
12.02.26 - 03:12
Neurocrine (NBIX) Q4 2025 Earnings Call Transcript (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
12.02.26 - 02:18
Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.02.26 - 01:00
Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
 
While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....
12.02.26 - 01:00
Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates (Zacks)
 
Neurocrine (NBIX) delivered earnings and revenue surprises of -16.55% and +2.89%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...
12.02.26 - 00:01
Neurocrine übertrifft Prognosen für Q4 2025 – Aktie legt zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
11.02.26 - 22:30
Neurocrine Biosciences Inc Profit Advances In Q4 (AFX)
 
WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc (NBIX) announced earnings for its fourth quarter that Increases, from last yearThe company's earnings came in at $153.7 million, or $1.48 per shar......
11.02.26 - 22:09
Neurocrine Biosciences Non-GAAP EPS of $1.88 misses by $0.42, revenue of $805.5M beats by $16.2M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
11.02.26 - 22:03
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 (PR Newswire)
 
Total Fourth-Quarter and Full-Year 2025 Net Product Sales of $798.3 Million and $2.83 Billion, Representing Year-Over-Year Growth of 29% and 22%, Respectively INGREZZA® (valbenazine) Full Year 2026 Net Product Sales Guidance of $2.7 - $2.8 Billion SAN DIEGO, Feb. 11, 2026 /PRNewswire/ --......
06.02.26 - 16:45
Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS (Zacks)
 
Get a deeper insight into the potential performance of Neurocrine (NBIX) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics....
04.02.26 - 17:30
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
 
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
26.01.26 - 14:33
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia (PR Newswire)
 
SAN DIEGO, Jan. 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is a next-generation, selective inhibitor of the......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!